APPLICATIONS PUBLISHED 22 DECEMBER 2004
Published: 14-Dec-2005
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Agent for oral administration and method for producing the same
Beisel, Guenther 1487405*
Heat-reversible compsn treating hyposalia and asialia
Ellipse Pharmaceuticals 1487406*
Site specific delivery of co-administered drugs via inhalation
Microdose Technologies 1487407*
Topical compsn based on ion-exchange resins, in particular for treating erythemas
Ellipse Pharmaceuticals 1487408*
Highly aqueous liquid carrier formulations
Battellepharma 1487409*
Preparation of sterile stabilised nanodispersions
Labopharm; Labopharm Europe; Labopharm (Barbados) 1487410*
Inhalable sustained therapeutic formulations
Advanced Inhalation Research 1487411*
Chemosensitising with liposomes containing oligonucleotides
Georgetown University; Neopharm 1487412*
An inhalation system for prevention and treatment of intracellular infections
Transave 1487413*
Antibiotic compsn
Advancis Pharmaceutical 1487414*
Method for the production and use of microparticles and nanoparticles by constructive micronisation
Pharmatech 1487415*
Drug microparticles
Teva Pharmaceuticals 1487416*
Dry powder medicament formulations
Glaxo Group 1487417*
Co-beadlet of DNA and rosemary and methods of use
Alcon 1487418*
Fast dissolving dosage forms having reduced friability
Elan Pharma International 1487419*
Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
BASF 1487420*
Pharmaceutical formulation for the active ingredient budesonide
Roehm 1487421*
Film coatings with controlled release and high stability
BASF 1487422*
Novel formulation
AstraZeneca 1487423*
4-(4-methylpiuperazin-1-ylmethyl)-N-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino{phenyl)-benzamide for treating ANG II-mediated diseases
Novartis 1487424*
Use of a vanilloid as an anti-snoring element
Lmd 1487425*
Methods of inducing terminal differentiation
Axon Pharma 1487426*
Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline
Somerset Pharmaceuticals 1487427*
Amino substituted (E)-2,6-dialkoxystyryl 4-substituted nemzyl sulphones for treating proliferative diseases
Temple University of the Commonwealth System of Higher Education 1487428*
Compsn of venlafaxine base
Synthon 1487429*
Methods of treating diseases related to intraocular pressure
Icagen 1487430*
Preventing and/or treating cardiovascular disease and/or associated heart failure
Protemix Corp 1487431*
Suramin and derivatives thereof as a topical microbicide and contraceptive
Eastern Virginia Medical School 1487432*
Anti-cancer combinations of DMXAA and a NSAID
Cancer Research Technology 1487433*
Botanical extract compsns with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
The Medical Research and Education Trust 1487434*
Azetidine derivatives as CCR-3 receptor antagonists
Novartis 1487435*
Combination therapy for treating, preventing or managing proliferative disorders and cancers
Signal Pharmaceuticals 1487436*
Methods of treatment with selective EP4 receptor agonists
Pfizer Products 1487437*
Compsns and methods for treating glaucoma and ocular hypertension
Merck 1487438*
Solubilisation of weak bases
The Arizona Board of Regents, on behalf of the University of Arizona 1487439*
A use of treatment for fungal infections with a synergistic formulation of antifungal agents
Council of Scientific and Industrial Research 1487440*
Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
Glaxo Group 1487441*
Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor
Applied Research Systems 1487442*
Heterocyclic amide derivatives for the treatment of diabetes and other diseases
Incyte San Diego 1487443*
Use of pyridyl amides as inhibitors of angiogenesis
Fujisawa Deutschland 1487444*
Obidoxime dimesylate
Drug Discovery Laboratory 1487445*
Bicyclic heterocycles for the treatment of diabetes and other diseases
Incyte San Diego 1487446*
Use of proton pump inhibitors for the treatment of airway disorders
Altana Pharma 1487447*
Treatment of effect of chemicals with their ultradilute stereoisomers
Sempach PTY 1487448*
Tyrosyl derivatives and their use as P2X7 receptor modulators
King Pharmaceuticals Research & Development 1487449*
Process for the preparation of antiviral 7-azaindole derivatives
Bristol-Myers Squibb 1487450*
Inhibition of cell death responses induced by oxidative stress
Dana-Farber Cancer Institute 1487451*
Use of 4-(4-methylpiperazin-1-ylmethyl)-N 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl-benzamide for treating seminomas
The Government of the United States of America as represented by the Department of Veterans Affairs 1487452*
N-[(2S)-4-(3,4-difluorobenzyl)morpholin-2-yl]methyl-2-3-(methylsulphonyl)amino]phenyl acetamide as CCR3 antagonist for the treatment of conditions
Glaxo Group 1487453*
Morpholine derivatives substituted at the 2-position by a heterocyclylalkylurea group for use as CCR-3 antagonists in the treatment of inflammatory conditions
Glaxo Group 1487454*
Morpholine derivatives substituted at the 2-position by an arylalkylurea group for use as CCR-3 antagonists in the treatment of inflammatory conditions
Glaxo Group 1487455*
Benzene sulphonate salt of a morpholine urea derivative for use as a CCR-3 antagonist in the treatment of inflammatory conditions
Glaxo Group 1487456*
Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation
Pfizer Products 1487457*
Multi-substituted selective androgen receptor modulators and methods of use thereof
The University of Tennessee Research Corp 1487458*
Peptide analogues and uses thereof
Ariad Pharmaceuticals 1487459*
Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogues and uses thereof
A&D Bioscience 1487460*
Methods of using and compsns comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
Celgene 1487461*
Preparations for topical skin use and treatment
Dow Corning 1487462*
Local production and/or delivery of anticancer agents by stromal cell precursors
Board of Regents, The University of Texas System 1487463*
Increasing tumour oxygen content by administration of stressed cells
Ichim, Thomas 1487464*
Purified cytokine inhibitory factor
Arklon Life Sciences 1487465*
Use of Lactobacillus farciminis for the prevention or pathology of digestive pathologies
Institute National de la Recherche Agronomique 1487466*
Bioactive hexane fraction from Vetiveria zizanioides
Council of Scientific and Industrial Research 1487467*
Plant extracts and the use thereof
Lichtwer Pharma 1487468*
Co-beadlet of DHA and rosemary and methods of use
Alcon 1487469*
Identification of free-B-ring flavinoids as potent COX-2 inhibitors
Unigen Pharmaceuticals 1487470*
Method for treating autoimmune disorders and reagents related thereto
Trustees of Tufts College 1487471*
Stabilisation of hypoxia inducible factor (HIF) alpha
Fibrogen 1487472*
Diagnostics and therapeutics for diseases associated with homo sapiens formyl peptide receptor-like 2
Bayer HealthCare 1487473*
Intranasal administration of MC4-R agonists
Chiron Corp 1487474*
Use of enzyme inhibitors with aminopeptidase N and/pr dipeptidylpeptidaseI V activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differential states
Institut fuer Medizintechnologie Magdeburg 1487475*
Use of angiotensin 1-7 for enhancing cardiac function
Citeq 1487476*
Methods of using FLT3-ligand in immunisation protocols
Immunex Corp 1487477*
Interferon-beta-like molecules for treatment of stroke
Maxygen 1487478*
Mutant glycoproteins
Applied Research Systems 1487479*
Fusion molecules and methods for treatment of immune diseases
The Regents of the University of California 1487480*
Methods of treating nerve entrapment syndromes
Elan Pharmaceuticals 1487481*
DNA vaccine against proliferating endothelial cells and methods of use thereof
The Scripps Research Institute 1487482*
Chimeric infections DNA clones, chimeric procine circoviruses and uses thereof
Virginia Tech Intellectual Properties 1487483*
Use of mixtures of lipoproteins for vaccine production
Institut Pasteur de Lille; Centre National de la Recherche Scientifique; Universite de Lille II; Institit National de la Sante et de la Recherche Medicale; SEDAC-Therapeutics (Societe d'Etude et de Developpement de Antigenes Combinatoires) 1487484*
Imidazoquinolineamines as adjuvants in HIV DNA vaccination
Powdermed; Glaxo Group 1487486*
Methods and compsns for prevention, diagnosis, and treatment of cancer using bispecific molecules
Elusys Therapeutics 1487487*
Specific antibodies to amyloid beta peptide, pharmaceutical compsns and methods of use thereof
Mindset Biopharmaceuticals USA 1487488*
Methods of preventing or treating disorders by administering an integrin AVB3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
Medimmune 1487489*
Combination methods of inhibiting tumour growth with a vascular endothelial growth factor receptor antagonist
Imclone Systems 1487490*
Nocvel use of cytokine inhibitors
Orthopaedic Research & Development in Gothenburg 1487491*
The prevention or treatment of cancer using integrin alphabeta3 antagonists in combination with other agents
Medimmune 1487492*
Conjugates of therapeutic or cytotoxic agents and biologically active peptides
The Administrators of the Tulane Educational Fund 1487493*
Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
North Shore-Long Island Jewish Research Institute 1487494*
Combination comprising a CDK inhibitor and doxorubicin
Cyclacel 1487495*
Test system for evaluating the compatibility of biologically active substances with copolymers
Abbott 1487496*
Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment
Wolf, Hand Joachim 1487497*
Topical compsn comprising a cyclofructan, a carrier and a drug
Novartis 1487498*
Contrast agents for magnetic resonance imaging and methods related thereto
Carnegie Mellon University 1487499*
Monitoring marker
AGA AB 1487500*
A phosphatase associated with metastasis
The Johns Hopkins University 1487501*
Formation of neolignan by DDQ mediated dimerisation of dihydroasarone
Council of Scientific and Industrial Research 1487770*
Fluorination of dicarbonyl compounds
F2 Chemicals 1487771*
Cyclopentadienone derivatives, their preparation and use in medicine
Charterhouse Therapeutics 1487772*
Method for the measurement of the pressure in a gas phase from rectification and/or absorption columns comprising (meth)acrylic acid the esters and nitriles thereof
BASF 1487773*
Bipolar trans carotenoid salts and their uses
Diffusion Pharmaceuticals 1487774*
Methods of manufacturing beta-hydroxycarboxylic acids
Cargill 1487775*
Acid and ester compounds and methods of using the same
SmithKline Beecham 1487776*
Process for the production of diaminodiphenylmethane and its higher homologues
Huntsman International 1487777*
Substituted 4-aminocyclohexanols
Gruenenthal 1487778*
Haloacetamide and azide substituted compounds and methods of use thereof
The University of Tennessee Research Corp 1487780*
Process for preparing 2-aminoindan derivatives
Novartis 1487781*
Process for preparing nateglinide and intermediates thereof
Teva Pharmaceuticals 1487782*
Irreversible selective androgen receptor modulators and methods of use thereof
University of Tennessee Research Foundation 1487783*
Novel trifuoromethylepinephrine compounds and methods of making and using thereof
US Army Medical Research and Materiel Command 1487784*
Novel florfenicol-type antibiotics
Schering-Plough 1487785*
2-substituted acrylamides, methods for production thereof and agents comprising the same
BASF 1487786*
Derivatives and pharmaceutical compsns of N-hydroxyalkyl tetramethylcyclopropane-carboxamide, having anti-epileptic, neurological and CNS activity, and method for their preparation
Yissum Research Development Company of the Hebrew University of Jerusalem 1487787*
Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
Glaxo Group; Cambridge University Technical Services; The Catholic University of Nijmegen 1487788*
Improvements in pharmaceutical compsns
Charterhouse Therapeutics 1487789*
Purified lasofoxifene and a method for purification by racemic lasofoifene by recrystallisation
Pfizer Products 1487790*
A novel antifungal molecule 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-2-yl)-methylethylpentanoate
Council of Scientific and Industrial Research 1487791*
Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
Eli Lilly 1487792*
Piperadine derivatives useful as modulators of cytokine receptor activity
AstraZeneca 1487793*
Monocyclic aroylpyridinones as anti-inflammatory agents
Bayer 1487794*
Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
Anormed 1487795*
Substituted biaryl amides as C5A receptor modulators
Neurogen Corp 1487796*
Hetero-bridge substituted 8-arylquinoline PDE4 inhibitors
Merck Frosst Canada 1487797*
Substituted tetrahydroisoquinlines as C5A receptor modulators
Neurogen Corp 1487798*
9-aminoacridine derivatives and process for the preparation thereof
Samjin Pharmaceuticals 1487799*
Phenanthridineones as PARP inhibitors
Fujisawa Pharmaceutical 1487800*
7-aryl-sulphoamino-2,3,4,5-tetrahydro-1H-benzo[D]azepine derivatives with 5-HT6 receptor affinity for the treatment of CNS disorders
Glaxo Group 1487801*
Neurotensin active 2,3-diaryl-pyrazolidine derivatives
Solvay Pharmaceuticals 1487802*
Indazoles substituted with an anti-cancerous activity
Aventis Pharma 1487803*
Aminoindazole derivatives as protein-kinase inhibitors
Aventis Pharma 1487804*
Pyrimidine derivatives
Novartis 1487805*
4-anilino quinazoline derivatives as antiproliferative agents
AstraZeneca 1487806*
New compounds
Sanofi-Aventis 1487807*
Process for the preparation of morpholine derivatives and intermediates therefore
Glaxo Group 1487809*
4-(diarylmethyl)-1-piperazinyl derivatives
Sun Pharmaceutical Industries 1487810*
N-sulphonylurea-apoptosis promoters
Abbott Laboratories 1487811*
Anomeric derivatives of monosaccharides
Alchemia 1487812*
Benzofuran and benzothiophene derivatives useful in the treatment of hyperproliferative disorders
Bayer Pharmaceuticals 1487813*
Process for the preparation of 4-oxytetrahydropyran-2-ones
Krka Tovarna Zdravil 1487814*
Compounds for the controlled release of active aldehydes
Firmencih 1487815*
Ether lactone
Kao Corp 1487816*
Piperidine derivatives useful as modulators of chemokine receptor activity
AstraZeneca 1487818*
Azepane derivatives and their use as ATK1 inhibitors
F Hoffmann-La Roche 1487819*
Crystalline forms of rabeprazole sodium
Dr Reddy's Laboratories 1487820*
Benzodiazepine-substituted piperidines for utilisation in the treatment of cardiovascular diseases
Boehringer Ingelheim Pharma 1487821*
Pyrrole-2,5-dione derivatives and their use as GSK-3 inhibitors
Eli Lilly 1487822*
Derivatives of 4-(imidazol-5-yl)-2-(4-sulphoanilino)pyrimidine with CDK inhibitory activity
AstraZeneca 1487823*
Diamino-pyrimidines and their use as angiogenesis inhibitors
SmithKline Beecham Corp 1487824*
Process to obtain dibenzylbutyrolactonic lignans; process to obtain synthetic derivatives from lignanes bearing anti-chagas chemoprophylactic and therapeutical activities
Fundacao de Amparo a Pesquisa do Estado de Sao Paolo 1487825*
New crystalline forms of (2S)-N-5-amino(imino)methyl-thienylmethyl-1-diphenylpropanoyl-2-pyrrolidine-carboxamide NH20
LG Life Sciences 1487826*
Anti-inflammatory morpholin-acetamide derivatives
Glaxo Group 1487827*
Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
Glaxo Group 1487828*
Thiadiazolylpiperazine derivatives useful for treating or preventing pain
Euro-Celtique 1487829*
Novel crystalline for of 5-(4-((3-methyl-4-oxo-,34-dihydroquinazolin-2-yl)methoxy)benzyl)thiazolidine-2,4-dione potassium salt
Dr Reddy-s Laboratories 1487830*
Difurylglycolic acid tropenol esters use as anticholinesterase drugs
Boehringer Ingelheim 1487831*
Micronized crystalline tiotropium bromide
Boehringer Ingelheim 1487832*
Process for preparing a pharmaceutically active compound (granisetron)
Laboratoires Vita 1487834*
Amides of acetic and propionic acids
Bayer 1487835*
Ethane-1,2-diamino-bis (2R)-2-bromo-3-phenylpropanoate], method for production and use thereof
Aventis Pharma Deutschland 1487836*
An improved process for the production of vasicine
Council of Scientific and Industrial Research 1487837*
Method and system for separation and purification of at least one narcotic alkaloid using reverse phase preparative chromatography
Mallinckrodt 1487838*
Methods for producing norgalanthamine, as well as isomers, salts and hydrates thereof
Sanochemia Pharmazeutica 1487839*
Crystalline polymorphic form of irinotecan hydrochloride
Pharmacia Italia 1487840*
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
Abbott Laboratories 1487841*
An optically active pyridine derivative and a medicament containing the same
Bayer HealthCare 1487842*
Substituted phenylacetic acids
Metabolex 1487843*
Process for the preparation of trihydrocarbylsilylated carboxylate monomers
Sigma Coatings 1487844*
Phosphinometallocenylamides as novel ligands for asymmetric catalysis
Eastman Chemical 1487845*
Process for improving sucralose purity and yield
Tate & Lyle 1487846*
A simple process for obtaining beta-aescin from indian horse chestnut (Aesculus indica)
Council of Scientific and Industrial Research 1487847*
A building block forming a C=C double bond upon reaction
Nuevolution 1487848*
A building block capable of transferring a functional entity
Nuevolution 1487849*
A building block forming a C-C or a C-hetero atom bond upon reaction
Nuevolution 1487850*
A building block capable of functional entity transfer to neucleophile
Nuevolution 1487851*
Anti-protozoal vaccine
The Council of the Queensland Institute of Medical Research 1487852*
